Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 2/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8460711 | 0.79 | ALDH1A1 (0.31) | NAALAD2ALDH1A1 | |
| SCHEMBL8458007 | 0.77 | ALDH1A1 (0.35) | NAALAD2ALDH1A1 | |
| SCHEMBL7111437 | 0.74 | NAALAD2 (0.44) | NAALAD2ALDH1A1LMNAMEN1CYP1A2 | |
| SCHEMBL3380551 | 0.73 | ALDH1A1 (0.41) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL8585562 | 0.73 | NAALAD2 (0.40) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL3382753 | 0.72 | NAALAD2 (0.42) | NAALAD2ALDH1A1LMNAMEN1CYP1A2 | |
| SCHEMBL8460189 | 0.71 | ALDH1A1 (0.40) | NAALAD2ALDH1A1LMNAMEN1CYP1A2 | |
| SCHEMBL3380370 | 0.70 | ALDH1A1 (0.39) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL3382732 | 0.68 | AKR1B1 (0.39) | NAALAD2ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL3952299 | 0.67 | ALDH1A1 (0.40) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | claimed |
| EP-1443954-B1 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | SCRIPPS RESEARCH INST (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1443954-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | Novartis Pharma GmbH (AT) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-5880112-A | PHOSPHINIC ACID DERIVATIVES; PROSTATE CANCER TREATMENT | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5804602-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5672592-A | HYDROLASE INHIBITORS, ANTITUMOR AND ANTICARCINOGENIC AGENTS, FOR PROSTATE CANCER | GUILFORD PHARMACEUTICALS INC. (US) | 1997-09-30 | — | — | US | disclosed |